Why the Recce Pharmaceuticals (ASX:RCE) share price is jumping 10% higher

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is jumping notably higher on Wednesday. Here's why it is on fire today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be dropping lower on Wednesday, but that hasn't stopped the Recce Pharmaceuticals Ltd (ASX: RCE) share price from jumping higher.

In afternoon trade the pharmaceutical company's shares are up almost 10% to $1.21.

This latest gain means the Recce share price is now up a massive 255% since the start of the year.

Why is the Recce share price jumping higher today?

Investors have been buying Recce shares on Wednesday after it announced an agreement with the Murdoch Children's Research Institute (MCRI) to conduct pre-clinical studies. The MCRI is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.

According to the release, these studies will assess the potential of RECCE 435 (R435) for the treatment of Helicobacter pylori (H. pylori) infections.

Management notes that there is a global unmet medical need for the treatment of H. pylori with no first-line therapy curative in all patients. In fact, the most commonly used treatment is triple therapy.

This includes the use of a Protein Pump Inhibitor in combination with multiple antibiotics. However, due to the increasing prevalence of antibiotic resistant strains worldwide, the eradication rate of standard triple therapy has fallen below 80%.

The company's Non-Executive Chairman, Dr. John Prendergast, commented: "Antibiotic-resistant forms of H. pylori are on the rise. This is worrisome because more than four billion worldwide are infected with H. pylori, which is the leading cause of peptic ulcers and stomach cancer."

"We are excited to collaborate with Professor Sutton and MCRI in investigating the potential of our oral anbitiotic RECCE 435 as what could be the first non-combination treatment for H. pylori infection, including those caused by drug resistant forms of the pathogen," he concluded.

Management expects to complete the trial in approximately 12 months, after which it will pursue a human clinical trial. It notes that it is well funded to support the study program following its recent successful capital raise.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »